A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria:

• Female participants aged ≥ 18 years.
• Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
• Platinum-resistant recurrent disease, defined as disease progression within 6 months (≤183 days) after the last platinum-based chemotherapy.
• At least one measurable lesion per RECIST v1.1.
• ECOG performance status of 0 or 1.
• Expected survival ≥ 12 weeks.
• Adequate organ and bone marrow function.
• Negative pregnancy test for women of childbearing potential, and agreement to use effective contraception.

Exclusion Criteria:

• Prior treatment with CLDN6-targeting therapy or topoisomerase I inhibitors (e.g., topotecan, trastuzumab deruxtecan).
• Active or untreated central nervous system (CNS) metastases or carcinomatous meningitis. (Patients with stable, treated CNS metastases may be eligible).
• Clinically significant cardiovascular disease, including QTc ≥ 470 ms, LVEF < 50%, or uncontrolled hypertension.
• Active infections (e.g., HBV, HCV, HIV, tuberculosis, syphilis).
• Active or history of autoimmune diseases requiring systemic treatment.
• Severe liver disease (Child-Pugh B or C), uncontrolled diabetes, or other severe medical conditions that may interfere with the study.